×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | Financial Markets | Infrastructure | Money | Vaccines | AstraZeneca | COVID antibody Evusheld

AstraZeneca Says US to Buy Additional 500,000 Doses of COVID Antibody

AstraZeneca
(AP)

Wednesday, 12 January 2022 02:07 PM

AstraZeneca said on Wednesday the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to treat COVID-19.

The company said the delivery of the doses was expected in the first quarter of 2022 and more details about the deal would be announced in the coming weeks.

The additional doses will add to previous purchase of 700,000 doses of the antibody therapy, which in December showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.

Only Authorized COVID-19 Antibody in the US

The U.S. Food and Drug Administration last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.

It is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure, the company said.

© 2022 Thomson/Reuters. All rights reserved.


StreetTalk
(Adds details on antibody therapy, background)Jan 12 (Reuters) - AstraZeneca said on Wednesday the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to treat COVID-19.The company said the delivery of the doses was...
AstraZeneca, COVID antibody Evusheld
145
2022-07-12
Wednesday, 12 January 2022 02:07 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved